FL-BACARDI-LIMITED
4.2.2020 13:17:10 CET | Business Wire | Press release
This Thursday, 7,000 Bacardi employees across the globe will turn on their “out of office” message to go out on the town and visit bars in more than 100 cities, all in the name of spotting what’s new and next for cocktails. The activity, called Back to the Bar, brings everyone at Bacardi together for a day of “barstool research” with bartenders who are the trend spotters and tastemakers of the spirits business and a direct link to consumers. According to Nielsen CGA, 40% of revenue in bars is influenced by bartenders as they are the go-to experts to help you pick your drink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200204005256/en/
As part of the third iteration of Back to the Bar, the largest privately-held spirits company sheds light on what's creating excitement for bartenders with the release of the Bacardi 2020 Cocktail Trends Report. The report highlights trends based on insights captured from a survey Bacardi ran with bartenders and bar ambassadors in 2019, as well as third-party research from the world’s leading consumer insights firms.
"Back to the Bar tradition is a time when everyone across the company, regardless of day job, becomes an ambassador and a researcher by going back to where our business is made – the local bars and restaurants," says Mahesh Madhavan, CEO of family-owned Bacardi Limited. "We are in the relationship business and I never miss an opportunity to talk to a bartender or our consumers to learn what they’re seeing and what they think will be the next big thing.”
As the company celebrates its 158th anniversary this week, Back to the Bar also commemorates the company’s legacy of a founder’s mentality and entrepreneurial spirit. For seven generations, the family-owned business has instilled a belief that brands are built in bars, not boardrooms. Everyone at Bacardi participates in this “roll-up your sleeves” approach to data collection and serves as influencers by talking to friends, family, and consumers about the brands.
“In an era where people are flooded with data, there is no substitute for putting feet on the street and seeing first-hand what’s happening at the bar," says Jacob Briars, Global Advocacy Director at Bacardi. “When something excites the bartenders, we know that it is a matter of time before we start to see a shift in the mindset and behavior of our guests.”
Among the findings of the Bacardi 2020 Cocktail Trends Report are that:
- Mindful drinking goes mainstream, with 83% of bartenders citing that low-alcohol drinks are hot and an increase of 42% in the online searches with the word 'mocktail' in 2019. (Technomic Behind the Bar Insights, 2019 and Google Trends, 2019)
- Natural products are in the spotlight with 31% of bartenders increasingly interested in local, fresh ingredients. (Global Brand Ambassador Survey (GBAS), 2019)
- The culinary cocktail trend borrows methods and techniques from the kitchen and champions fresh, seasonal, savory and herbal ingredients – 91% of bartenders use vegetables in their cocktails, and 68% of American Culinary Federation members rated culinary cocktail as a 'hot trend' last year. (Technomic Behind the Bar Insights, 2019)
- Dark rum is leading the premium game – 43% of bartenders ranked it as the top spirit to premiumize. (GBAS, 2019)
- Sustainability is at the forefront of every consumer's mind, and it's reflected in the bar – 66% of bartenders mention that sustainable drinks are hot right now. (Technomic Behind the Bar Insights, 2019)
- Ready-To-Drink (RTD) cocktails are here to stay, reflecting the overarching demand for consistent and convenient well-crafted cocktails beyond the bar – there was a 26% increase of vodka soda and flavored RTDs in North America last year. (GBAS, 2019)
- 38% of Americans prefer to make their cocktails at home, and the industry has quickly adapted, offering consumers myriad ways to facilitate at-home imbibing, from home cocktail kits to AI-recommended recipes. (Mintel, 2019)
Click here to access the complete Bacardi 2020 Cocktail Trends Report .
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates more than 20 production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
